



# Mepsevii in India

*The CDSCO named-patient coordination pathway — indicative 2026*

RARE DISEASE · MPS VII (SLY SYNDROME)

## The clinical situation

Mepsevii (vestronidase alfa) is an FDA-approved recombinant human beta-glucuronidase enzyme replacement therapy for mucopolysaccharidosis type VII (Sly syndrome), dosed 4 mg/kg IV every two weeks. Manufactured by Ultragenyx. Weight-based dosing, cold-chain shipment, and monitoring of pulmonary, cardiac, and skeletal disease manifestations are required.

### The pathway, 5 steps

- 1 Consultation & diagnostic confirmation.** Treating metabolic specialist confirms GUSB deficiency and MPS VII phenotype; weight-based dose calculated.
- 2 Infusion centre confirmed.** An Indian tertiary metabolic centre (Delhi, Mumbai, Chennai, Bengaluru) commits to biweekly infusion slots and multisystem monitoring.
- 3 CDSCO named-patient application.** Form 12A / personal-import documentation is filed with enzyme assay, dose calculation, and product details for CDSCO review.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; refrigerated shipment booked.
- 5 Infusion & monitoring.** Biweekly IV infusions under specialist supervision; pulmonary, cardiac, and skeletal monitoring per label.

### Indicative economics

**Reference US cash-pay range:** USD 35,000–45,000 per infusion (weight-based) drug-only. Cold-chain logistics, CDSCO documentation, infusion-centre fees, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-infusion timing

**7–14 days** from a complete CDSCO application to first-infusion delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** CDSCO named-patient / Form 12A package with enzyme-assay confirmation. **Logistics.** Cold-chain, temperature-monitored shipment coordination.

**Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating specialist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Mepsevii × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/mepsevii-india.html](https://reservemed.com/access-guides/mepsevii-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team